Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European Journal of Clinical Pharmacology

Volumn 68, Issue 7, 2012, Pages 1049-1056

  Kosoglou, Teddy ^a   Kraft, Walter K ^b   Kumar, Bharath ^a   Statkevich, Paul ^a   Xuan, Fengjuan ^a   Ma, Lei ^a   Jennings, Lisa K ^c   Schiller, James E ^a   Langdon, Ronald B ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

PAR 1; Pharmacodynamics; Pharmacokinetics; Renal disease; SCH 530348; Vorapaxar

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VORAPAXAR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LACTONES; MALE; MIDDLE AGED; PLATELET AGGREGATION; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; RENAL DIALYSIS; YOUNG ADULT;

EID: 84864286320     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1217-6     Document Type: Article

References (25)

1. Davies MJ, Woolf N, Robertson WB (1976) Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J 38:659-664
2. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH (2000) Unstable angina pectoris. N Engl J Med 342:101-114 (Pubitemid 30036603)
3. Lip GY, Kamath S, Hart RG (2002) ABC of antithrombotic therapy: antithrombotic therapy for cerebrovascular disorders. Br Med J 325:1161-1163 (Pubitemid 35398716)
4. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
5. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106
6. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
7. Dogne JM, de Leval X, Benoit P, Delarge J, Masereel B, David JL (2002) Recent advances in antiplatelet agents. Curr Med Chem 9:577-589 (Pubitemid 34436435)
8. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717
9. Angiolillo DJ, Capodanno D, Goto S (2010) Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31:17-28
10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
11. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
12. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 96:11189-11193 (Pubitemid 29487356)
13. Brummel KE, Paradis SG, Butenas S, Mann KG (2002) Thrombin functions during tissue factor-induced blood coagulation. Blood 100:148-152 (Pubitemid 35177440)
14. Mann KG (2003) Thrombin formation. Chest 124:4S-10S (Pubitemid 37128430)
15. Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103 [3 Suppl]:4A-10A
16. Chackalamannil S (2003) G-protein coupled receptor antagonists. I. Protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. Curr Top Med Chem 3:1115-1123
17. Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow G, Foster C, Agans-Fantuzzi J, Bryant M, Lau J, Chintala M (2005) Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 48:5884-5887 (Pubitemid 41324598)
18. Chackalamannil S (2006) Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 49:5389-5403 (Pubitemid 44373171)
19. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156-164
20. Shinohara Y, Goto S, Doi M, Jensen P (2010) Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis doi:10.1016/j. jstrokecerebrovasdis.2010.09.005
21. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA, for the TRA-PCI Investigators (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919-928
22. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E, for the TRA 2°P-TIMI 50 Investigators (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J 158:335-341
23. *CER) trial: study design and rationale. Am Heart J 158:327-334.e4
24. Kosoglou T, Reyderman L, Tiessen RG, van Vliet AA, Fales RR, Keller R, Yang B, Cutler DL (2011) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol doi:10.1007/s00228-011-1120-6
25. Kosoglou T, Reyderman L, Kasserra C, Jennings LHK, Young S, Xuan F, Pei J, Maxwell SE, Meehan AG, Cutler DL (2011) No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol doi:10.1007/s00228011-1127-z